Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with histopathologic diagnosis of well-differentiated neuroendocrine tumour or carcinoma according to WHO classification~* patients who, according to RECIST criteria (Response Evaluation Criteria in Solid Tumours) present measurable disease~* patients with progressive disease in the previous 6 months before their inclusion in the study~* patients with positive IN111 octreotide scintigraphy~Exclusion Criteria:~* patients with surgically removable localised disease~* patients with progressive disease in the first six months of being diagnosed~* patients with intestinal obstruction due to a carcinoid tumour~* patients who have received treatment with somatostatin analogues during the 6 months before being included in the study~* patients who have received treatment with radiotherapy, chemotherapy or interferon 4 weeks before being included in the study, or planned to receive these during the study~* patients who have received treatment with liver artery embolisation or radiopharmaceuticals (endoradiotherapy) 12 weeks before being included in the study, or planned during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).